July 12 was a very good day for Novartis AG.
FDA’s Oncologic Drugs Advisory Committee unanimously recommended approval (10-0) of the company’s CAR-T immunotherapy CTL019 (tisagenlecleucel)
Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirming no panel will be scheduled, according to the firm. But the company and FDA may have benefited from an advisory committee review.
July 12 was a very good day for Novartis AG.
FDA’s Oncologic Drugs Advisory Committee unanimously recommended approval (10-0) of the company’s CAR-T immunotherapy CTL019 (tisagenlecleucel)